<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5351">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144026</url>
  </required_header>
  <id_info>
    <org_study_id>THYMON-10001</org_study_id>
    <nct_id>NCT01144026</nct_id>
  </id_info>
  <brief_title>Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects</brief_title>
  <acronym>THYMON-10001</acronym>
  <official_title>Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thymon, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thymon, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol represents the second in human study of TUTI-16, and is being conducted to
      continue to gather safety and human immunogenicity (anti-HIV-1 Tat titers) data of
      subcutaneously administered TUTI-16.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 Tat protein, a virally encoded toxin, is secreted by HIV-1 infected cells and acts on
      uninfected cells, rendering them permissive for HIV-1 replication. HIV-1 Tat enhances
      chronic viral replication and induces immune suppression. Antibodies to Tat inhibit this
      Tat-mediated transcellular activation in vitro and minimize chronic plasma viremia. HIV-1
      Tat activities can be blocked in vitro and in vivo by anti-Tat antibodies.

      The Thymon Universal Tat Immunogen (TUTI-16) is a fully synthetic, self-adjuvanting
      lipopeptide vaccine that is water soluble and administered by subcutaneous injection. In
      preclinical studies, a priming dose and a three week boost in rats induced a high titer
      antibody response to the eight known distinct epitope variants of HIV-1 Tat protein. These
      antibodies block the function of the HIV-1 Tat protein (toxin), which is essential to the
      maintenance of chronic HIV-1 viremia. Therefore, TUTI-16 has potential as a therapeutic
      vaccine for HIV-1 in humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Anti-Tat Antibody Titer</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ELISA based chemiluminescent assay to determine the anti-Tat antibody response</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>TUTI-16 (0.2mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TUTI-16 (1.0 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TUTI-16 (0.2mg)</intervention_name>
    <description>Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.</description>
    <arm_group_label>TUTI-16 (0.2mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TUTI-16 (1.0 mg)</intervention_name>
    <description>Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.</description>
    <arm_group_label>TUTI-16 (1.0 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females

          -  Age ≥18 and ≤50 years at Screening

          -  HIV negative healthy subjects or HIV-1 seropositive subjects on effective ART for &gt;2
             months (undetectable HIV plasma viremia), viral set point before ART &gt;3,000

          -  CD4+ T-cell count ≥ 500/mm3.

        Exclusion Criteria:

          -  Pregnant/nursing females

          -  Positive for HBV or HCV

          -  Acute Herpetic event

          -  Any clinically significant out-of range laboratory value

          -  Routine or PRN consumption of immune suppressive medications that the subject is
             unable or unwilling to discontinue during the study

          -  Participation in another investigational drug/vaccine study within 30 days preceding
             the first injection of investigational agent in this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mardik Donikyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinilabs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinilabs</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 14, 2013</lastchanged_date>
  <firstreceived_date>June 12, 2010</firstreceived_date>
  <firstreceived_results_date>December 7, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>vaccine</keyword>
  <keyword>lipopeptide</keyword>
  <keyword>Tat</keyword>
  <keyword>TUTI-16</keyword>
  <keyword>THYMON</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TUTI-16 (0.2mg)</title>
          <description>Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.</description>
        </group>
        <group group_id="P2">
          <title>TUTI-16 (1.0 mg)</title>
          <description>Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TUTI-16 (0.2mg)</title>
          <description>Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.</description>
        </group>
        <group group_id="B2">
          <title>TUTI-16 (1.0 mg)</title>
          <description>Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38.4" spread="8.51"/>
                <measurement group_id="B2" value="36.4" spread="4.56"/>
                <measurement group_id="B3" value="38.4" spread="7.64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Tat Antibody Titer</title>
        <description>ELISA based chemiluminescent assay to determine the anti-Tat antibody response</description>
        <time_frame>5 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>all participants enrolled were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>TUTI-16 (0.2mg)</title>
            <description>Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.</description>
          </group>
          <group group_id="O2">
            <title>TUTI-16 (1.0 mg)</title>
            <description>Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-Tat Antibody Titer</title>
            <description>ELISA based chemiluminescent assay to determine the anti-Tat antibody response</description>
            <units>ng/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="401" lower_limit="0" upper_limit="2565"/>
                  <measurement group_id="O2" value="887" lower_limit="99" upper_limit="2286"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TUTI-16 (0.2mg)</title>
          <description>Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.</description>
        </group>
        <group group_id="E2">
          <title>TUTI-16 (1.0 mg)</title>
          <description>Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gideon Goldstein</name_or_title>
      <organization>Thymon LLC</organization>
      <phone>(973) 467-9558</phone>
      <email>gidgold@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
